Priority Health Teams Up with Virta Health for Diabetes, Weight Loss Support
Priority Health has partnered with Virta Health to offer a suite of diabetes and weight management solutions to its employer clients.
Why Is Medtronic Spinning Off Its Diabetes Business?
Medtronic’s move to turn its diabetes division into a separate company allows it to step away from a lower-profit, consumer-oriented segment of its business, while also giving the diabetes unit more room to focus and compete in its own crowded market.
presented by
The Top 5 Home Care Franchise Opportunities in the U.S.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
Aeroflow Health Unveils New Diabetes Management Program
Aeroflow Health has launched a new diabetes program that offers educational content on diabetes management, medical nutrition therapy and more.
The Role of Medication Delivery in Non-Adherence
For GLP-1 receptor agonists specifically, adherence challenges are a major concern, as these medications require long-term use to achieve meaningful health benefits in chronic conditions like diabetes and obesity.
Medicare Part D Spending on 10 Diabetes Drugs Hit $35.8B in 2023
Medicare Part D spending on 10 diabetes drugs increased 364% between 2019 and 2023.
Prioritizing CKD Screening Guidelines is Imperative to Combat Global Health Crisis
The consequences for not prioritizing new guidelines for CKD screening have a devastating impact on population health by increasing the global mortality rate and driving higher healthcare costs.
What Are Healthcare Organizations Getting Wrong about Email Security?
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
Food as Health: Shifting from Treatment to Prevention of Diet-Related Disease
Overcoming the systemic, structural and cultural issues that lead to poor nutrition is complex, making it even more essential for both private and public investment in food as health programs and policies that have been shown to be effective.
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender
Corxel Pharmaceuticals has acquired an oral small molecule GLP-1 agonist with potential applications in obesity and diabetes. The Phase 2-ready pill could compete with oral metabolic meds in development by companies such as Roche, AstraZeneca, and Structure Therapeutics.
Dexcom Adds Generative AI Platform to Its Over-the-Counter CGM
Dexcom recently became the first medical device company to embed generative AI into a continuous glucose monitor. Adding generative AI to the company’s Stelo glucose monitor will give users more personalized recommendations about how to improve their metabolic health, said Dexcom COO Jake Leach.
Closing America’s Diabetes Divide: A $412 Billion Opportunity to Transform Diabetes Care
By addressing each community’s unique needs with tailored, culturally responsive care and cross-sector collaboration, we can empower healthcare providers to drive lasting, equitable outcomes.
The Human Algorithm: What AI Can’t Replace in Pharma Engagement
At a time when AI is reshaping pharma, Reverba Global CEO Cheryl Lubbert explained in an interview why empathy, context, and ethics still require a human touch.
CGMs Aren’t Just for People with Diabetes Anymore, Dexcom COO Says
This week at HLTH, Dexcom COO Jake Leach discussed Stelo, his company's new product. Stelo is an over-the-counter continuous glucose monitor meant for all adults who don't take insulin.
Improved Access to CGM Data Empowers Providers and Patients to More Effectively Partner on Diabetes Management
Continuous Glucose Monitoring tools are revolutionizing the way diabetes is managed, offering unparalleled benefits for both healthcare providers and patients. By providing continuous, accurate data, CGM is especially useful for remote monitoring, enabling timely interventions and leading to better user health.
The Surprising Rivalries-Turned-Friendships That Are Shaping Diabetes Technology
Over the past decade, Abbott and Dexcom — the two largest makers of continuous glucose monitors — have been teaming up with medical device companies that sell automated insulin delivery systems. Industry experts think these partnerships are smart moves to stay relevant in the rapidly-developing diabetes care space.
FDA Says ‘No’ to Novo Nordisk’s Once-Weekly Insulin
The FDA rejected Novo Nordisk’s biologics license application for icodec, citing questions about the manufacturing process for this once weekly insulin as well as its use by type 1 diabetes patients. But there are several high-profile FDA approvals in our recap of recent regulatory news.
Abbott Says Its Latest CGM Sensor Is Its Most Discreet Yet
Abbott recently launched the FreeStyle Libre 3 Plus sensor, which it says is the smallest and most discreet sensor on the market. It will soon be available in U.S. retail pharmacies and medical equipment suppliers.